EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Research Progress of Proteasome Inhibitor MG132 in Treatment of Gynecologic Malignant Tumors

Xiaoyang Liu iD, Zizhang Li iD, Chengguo Zhang, Jun Liang, Nan Zhou

Journal of Biochemical and Molecular Toxicology · 2026

DOI: 10.1002/jbt.70725 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2026. Verfasst von Xiaoyang Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Hebei Medical University, Shijiazhuang, Hebei, China. Hauptthemen laut MEDLINE: Proteasome Inhibitors, Genital Neoplasms, Female, Leupeptins, Antineoplastic Agents. Die Arbeit nennt 86 Literaturangaben. Gefördert von: the Special Project for Scientific and Technological Innovation Talents under the Xingtai City innovation Capacity Enhancement Plan, the Three-Three-Three Talent Project of Hebei Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The ubiquitin‐proteasome system (UPS) is the primary mechanism for intracellular protein degradation, crucial in oncogenesis and tumor progression. Proteasome inhibitors disrupt UPS‐mediated proteolysis, effectively inhibiting neoplastic cell proliferation, and have become established therapeutic targets in oncology. Gynecologic malignant tumors pose a significant threat to women's reproductive health globally. Among proteasome inhibitors, MG132 has garnered extensive attention in gynecologic oncology due to its multifaceted mechanisms, including cell cycle regulation, NF‐κB signaling inhibition, and modulation of p53 activity. This review consolidates recent research on the therapeutic potential of MG132 in gynecologic malignant tumors, with a focus on its molecular mechanisms of action.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proteasome InhibitorsGenital Neoplasms, FemaleLeupeptinsAntineoplastic AgentsHumansFemaleProteasome Endopeptidase ComplexAnimalsSignal Transduction

Stichwörter der Autor:innen

MG132gynecologic malignant tumorsmechanisms of actionproteasome inhibitorubiquitin‐proteasome system

Substanzen

Proteasome Inhibitorsbenzyloxycarbonylleucyl-leucyl-leucine aldehydeLeupeptinsProteasome Endopeptidase ComplexAntineoplastic Agents

Autor:innen und Institutionen

  • Graduate School of Hebei Medical University, Shijiazhuang, Hebei, China.
  • Department of Gynecology, Xingtai People's Hospital, Xingtai, Hebei, China.
  • Department of Obstetrics and Gynecology, Hebei Medical University Third Hospital, Shijiazhuang, Hebei, China.

ORCID-Profile: Xiaoyang Liu, Zizhang Li

Förderung

  • the Special Project for Scientific and Technological Innovation Talents under the Xingtai City innovation Capacity Enhancement Plan
  • the Three-Three-Three Talent Project of Hebei Province

Zitieren

APA

Liu, X., Li, Z., Zhang, C., Liang, J., & Zhou, N. (2026). Research Progress of Proteasome Inhibitor MG132 in Treatment of Gynecologic Malignant Tumors. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.70725

Vancouver

Liu X, Li Z, Zhang C, Liang J, Zhou N. Research Progress of Proteasome Inhibitor MG132 in Treatment of Gynecologic Malignant Tumors. Journal of Biochemical and Molecular Toxicology. 2026. doi:10.1002/jbt.70725

BibTeX
@article{Liu2026,
  author = {Liu, Xiaoyang and Li, Zizhang and Zhang, Chengguo and Liang, Jun and Zhou, Nan},
  title = {Research Progress of Proteasome Inhibitor MG132 in Treatment of Gynecologic Malignant Tumors},
  journal = {Journal of Biochemical and Molecular Toxicology},
  year = {2026},
  doi = {10.1002/jbt.70725}
}
Kostenlos starten →